Anti-EGFR Antibody (Nimotuzumab)

Nimotuzumab is a humanized monoclonal antibody mainly used to treat head and neck squamous cell carcinoma and other solid tumors. It inhibits the proliferation and survival of tumor cells by targeting the epidermal growth factor receptor (EGFR) and blocking its signal transduction. Nimotuzumab is derived from combining the constant region of human antibodies with the variable region of mouse antibodies through genetic engineering technology. Its composition includes antibody molecules of the IgG1 subtype, which can specifically bind to and neutralize EGFR, interfering with the growth signal pathway of tumor cells.